Literature DB >> 17459610

A study of image-guided intensity-modulated radiotherapy with fiducials for localized prostate cancer including pelvic lymph nodes.

Annie Hsu1, Todd Pawlicki, Gary Luxton, Wendy Hara, Christopher R King.   

Abstract

PURPOSE: To study the impact on nodal coverage and dose to fixed organs at risk when using daily fiducial localization of the prostate to deliver intensity-modulated radiotherapy (IMRT). METHODS AND MATERIALS: Five patients with prostate cancer in whom prostate and pelvic nodes were irradiated with IMRT were studied. Dose was prescribed such that 95% of the prostate planning target volume (PTV) and 90% of the nodal PTV were covered. Random and systematic prostate displacements in the anterior-posterior, superior-inferior, and left-right directions were simulated to shift the original isocenter of the IMRT plan. The composite dose during the course of treatment was calculated.
RESULTS: Compared with a static setup, simulating random shifts reduced dose by less than 1.5% for nodal hotspot (i.e., dose to 1 cm(3)), by less than 1% for the 90% nodal PTV coverage, and by less than 0.5% for the nodal mean dose. Bowel and femoral head hotspots were reduced by less than 1.5% and 2%, respectively. A 10-mm systematic offset reduced nodal coverage by up to 10%.
CONCLUSION: The use of prostate fiducials for daily localization during IMRT treatment results in negligible changes in dose coverage of pelvic nodes or normal tissue sparing in the absence of a significant systematic offset. This offers a simple and practical solution to the problem of image-guided radiotherapy for prostate cancer when including pelvic nodes.

Entities:  

Mesh:

Year:  2007        PMID: 17459610     DOI: 10.1016/j.ijrobp.2007.02.030

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  15 in total

1.  Phantom measurements to quantify the accuracy of a commercially available cone-beam CT gray-value matching algorithm using multiple Fiducials.

Authors:  Frederick Marc Köhler; Judit Boda-Heggemann; Beate Küpper; Dirk Wolff; Hansjörg Wertz; Frank Lohr; Frederik Wenz
Journal:  Strahlenther Onkol       Date:  2009-02-18       Impact factor: 3.621

2.  Intensity-modulated radiotherapy (IMRT) to prostate and pelvic nodes-is pelvic lymph node coverage adequate with fiducial-based image-guided radiotherapy?

Authors:  G Eminowicz; C Dean; O Shoffren; N Macdougall; P Wells; R Muirhead
Journal:  Br J Radiol       Date:  2014-03-20       Impact factor: 3.039

Review 3.  Review of Real-Time 3-Dimensional Image Guided Radiation Therapy on Standard-Equipped Cancer Radiation Therapy Systems: Are We at the Tipping Point for the Era of Real-Time Radiation Therapy?

Authors:  Paul J Keall; Doan Trang Nguyen; Ricky O'Brien; Pengpeng Zhang; Laura Happersett; Jenny Bertholet; Per R Poulsen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-04-14       Impact factor: 7.038

4.  Investigation of dose perturbations and the radiographic visibility of potential fiducials for proton radiation therapy of the prostate.

Authors:  Jessie Y Huang; Wayne D Newhauser; X Ronald Zhu; Andrew K Lee; Rajat J Kudchadker
Journal:  Phys Med Biol       Date:  2011-07-28       Impact factor: 3.609

5.  Independent position correction on tumor and lymph nodes; consequences for bladder cancer irradiation with two combined IMRT plans.

Authors:  Dominique C van Rooijen; René Pool; Jeroen B van de Kamer; Maarten C C M Hulshof; Caro C E Koning; Arjan Bel
Journal:  Radiat Oncol       Date:  2010-06-15       Impact factor: 3.481

6.  Stereotactic body radiotherapy to the prostate and pelvic lymph nodes: A detailed dosimetric analysis of a phase II prospective trial.

Authors:  Amar U Kishan; Marguerite Tyran; Julius Weng; Shrinivasa Upadhyaya; James Lamb; Michael Steinberg; Christopher King; Minsong Cao
Journal:  Br J Radiol       Date:  2019-04-03       Impact factor: 3.039

7.  Dose perturbations from implanted helical gold markers in proton therapy of prostate cancer.

Authors:  Annelise Giebeler; Jonas Fontenot; Peter Balter; George Ciangaru; Ronald Zhu; Wayne Newhauser
Journal:  J Appl Clin Med Phys       Date:  2009-01-27       Impact factor: 2.102

8.  Impact of prostate focused alignment on planned pelvic lymph node dose.

Authors:  Joshua Kilian-Meneghin; Tianjun Ma; Lalith Kumaraswamy
Journal:  J Appl Clin Med Phys       Date:  2021-07-07       Impact factor: 2.102

9.  Optimal planning target volume margins for elective pelvic lymphatic radiotherapy in high-risk prostate cancer patients.

Authors:  Benjamin K Hinton; John B Fiveash; Xingen Wu; Michael C Dobelbower; Robert Y Kim; Rojymon Jacob
Journal:  ISRN Oncol       Date:  2013-03-07

10.  Does intensity modulated radiation therapy (IMRT) prevent additional toxicity of treating the pelvic lymph nodes compared to treatment of the prostate only?

Authors:  Matthias Guckenberger; Kurt Baier; Anne Richter; Dirk Vordermark; Michael Flentje
Journal:  Radiat Oncol       Date:  2008-01-11       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.